Meeting
2015 ASCO Annual Meeting
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.
Authors
Paolo Andrea Zucali
Department of Oncology, Humanitas Research Hospital - Humanitas Cancer Center, Rozzano, Italy
Paolo Andrea Zucali , Matteo Simonelli , Fabio De Vincenzo , Giuseppe Fatuzzo , Monica Bertossi , Matteo Perrino , Chiara Miggiano , Laura Giordano , Cristiana Bonifacio , Federica Mrakic Sposta , Armando Santoro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT02049060
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2549)
DOI
10.1200/jco.2015.33.15_suppl.2549
Abstract #
2549
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM).
First Author: Paolo A. Zucali
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2015 Genitourinary Cancers Symposium
Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer.
First Author: Wassim Abida
Poster
2014 ASCO Annual Meeting
Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.
First Author: Eve T. Rodler